[1] PRATT K, LORDO R, SELF S, et al. Amlodipine versus nifedipine ER for the management of postpartum hypertension: a noninferiority randomized controlled trial[J]. Am J Obstet Gynecol MFM, 2025, 7(1): 101575. doi:  10.1016/j.ajogmf.2024.101575
[2] LEONARD S A, SIADAT S, MAIN E K, et al. Chronic hypertension during pregnancy: prevalence and treatment in the United States,2008-2021[J]. Hypertension, 2024, 81(8): 1716-1723. doi:  10.1161/HYPERTENSIONAHA.124.22731
[3] SANUSI A A, LEACH J, BOGGESS K, et al. Pregnancy outcomes of nifedipine compared with labetalol for oral treatment of mild chronic hypertension[J]. Obstet Gynecol, 2024, 144(1): 126-134. doi:  10.1097/AOG.0000000000005613
[4] ALAVIFARD S, CHASE R, JANOUDI G, et al. First-line antihypertensive treatment for severe hypertension in pregnancy: a systematic review and network meta-analysis[J]. Pregnancy Hypertens, 2019, 18: 179-187. doi:  10.1016/j.preghy.2019.09.019
[5] SHIMAMOTO K, KIMOTO M, MATSUDA Y, et al. Long-term safety and efficacy of high-dose controlled-release nifedipine(80 mg per day)in Japanese patients with essential hypertension[J]. Hypertens Res, 2015, 38(10): 695-700. doi:  10.1038/hr.2015.54
[6] TUNG Y C, HSU T J, LIN C P, et al. Efficacy and safety outcomes of one generic nifedipine versus ADALAT long-acting nifedipine for hypertension management[J]. J Clin Hypertens, 2020, 22(12): 2296-2305. doi:  10.1111/jch.14070
[7] US Food and Drug Administration. How to make a FOIA request [EB/OL]. (2024-01-10) [2024-09-16]. https://www.fda.gov/regulatory-information/freedom-information/how-make-foia-request.
[8] Maintenance and Support Services Organization. Support Documentation: MedDRA Version 24.0(English)[EB/OL]. (2021-03)[2021-06-16]. https://www.meddra.org/how-to-use/support-documentation/english.
[9] RECORD WORKING COMMITTEE. RECORD Checklist [EB/OL]. (2015) [2021-06-16]. https://www.record-statement.org/checklist.php.
[10] VAN PUIJENBROEK E P, BATE A, LEUFKENS H G M, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions[J]. Pharmacoepidemiol Drug Saf, 2002, 11(1): 3-10. doi:  10.1002/pds.668
[11] BATE A, LINDQUIST M, EDWARDS I R, et al. A bayesian neural network method for adverse drug reaction signal generation[J]. Eur J Clin Pharmacol, 1998, 54(4): 315-321. doi:  10.1007/s002280050466
[12] ZHANG X, LIAO H, ZHU X J, et al. A successful pregnancy in a patient with secondary hypertension caused by adrenal adenoma: a case report[J]. BMC Pregnancy Childbirth, 2019, 19(1): 116. doi:  10.1186/s12884-019-2262-2
[13] DI PASQUO E, GIANNUBILO S R, VALENTINI B, et al. The “preeclampsia and hypertension target treatment” study: a multicenter prospective study to evaluate the effectiveness of the antihypertensive therapy based on maternal hemodynamic findings[J]. Am J Obstet Gynecol MFM, 2024, 6(5): 101368. doi:  10.1016/j.ajogmf.2024.101368
[14] SHI D D, YANG F Z, ZHOU L, et al. Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia[J]. J Clin Pharm Ther, 2016, 41(6): 657-661. doi:  10.1111/jcpt.12439
[15] KLEIN K L, SCOTT W J, WILSON J G. Aspirin-induced teratogenesis: a unique pattern of cell death and subsequent polydactyly in the rat[J]. J Exp Zool, 1981, 216(1): 107-112. doi:  10.1002/jez.1402160111
[16] ARULKUMARAN N, LIGHTSTONE L. Severe pre-eclampsia and hypertensive crises[J]. Best Pract Res Clin Obstet Gynaecol, 2013, 27(6): 877-884. doi:  10.1016/j.bpobgyn.2013.07.003
[17] OHISHI M. Hypertension with diabetes mellitus: physiology and pathology[J]. Hypertens Res, 2018, 41(6): 389-393. doi:  10.1038/s41440-018-0034-4
[18] PASCALL E, TULLOH R M. Pulmonary hypertension in congenital heart disease[J]. Future Cardiol, 2018, 14(4): 343-353. doi:  10.2217/fca-2017-0065
[19] CHAPMAN L, BURROWS-PEAKIN R, REGE V P, et al. Serum cystine aminopeptidase and the small-for-dates baby in hypertensive pregnancy[J]. Br J Obstet Gynaecol, 1976, 83(3): 238-240. doi:  10.1111/j.1471-0528.1976.tb00816.x